Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.

International journal of clinical pharmacology and therapeutics - 1 Mar 2015

Lozano Roberto, Franco María-Esther, López Luis, Moneva Juan-José, Carrasco Vicente, Pérez-Layo Maria-Angeles

Abstract excerpt

OBJECTIVE: Our aim was to determinate the acenocoumarol dose requirement in highly sensitive geriatric patients, based on a minimum of genotype (VKORC1 and CYP2C9) data. METHODS: We used a Gaussian kernel density estimation test to identify patients highly sensitive to the drug and PHARMACHIP®-Cuma test (Progenika Biopharma, SA, Grifols, Spain) to determine the CYP2C9 and VKORC1 genotype. RESULTS: All highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Dosage Calculations

Share to Drug Monitoring

Share to Pharmacogenetics

Share to Pilot Projects

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 25669612
DOI: 10.5414/CP202206

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.PMID 25669612Read ↗

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.Semantic proximity Read ↗

Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.Semantic proximity Read ↗

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Semantic proximity Read ↗

An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.Semantic proximity Read ↗

Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.Semantic proximity Read ↗

The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.Semantic proximity Read ↗

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Semantic proximity Read ↗

Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.Semantic proximity Read ↗

Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.Semantic proximity Read ↗

Genotype-guided coumarin dosing: where are we now and where do we need to go next?Semantic proximity Read ↗

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.